Update shared on15 Aug 2025
With no change in the discount rate or net profit margin, Alector’s consensus analyst price target remained stable at $4.51.
What's in the News
- Alector updated its 2025 collaboration revenue guidance to $13 million–$18 million.
- The company will see CFO Marc Grasso depart and be replaced by Chief Business Officer Neil Berkley as Interim CFO, while reporting progress in late-stage collaborations with GSK.
- Topline data from the pivotal INFRONT-3 Phase 3 trial of latozinemab in FTD-GRN is expected in Q4 2025, and enrollment was completed in the PROGRESS-AD Phase 2 trial of AL101 in early Alzheimer’s disease.
- Alector continues advancing preclinical programs using its Alector Brain Carrier platform for Alzheimer’s and Parkinson’s disease candidates.
- Alector was added to multiple Russell value and small/microcap indices, including the Russell 2000, 2500, 3000, and Microcap Value Benchmarks.
Valuation Changes
Summary of Valuation Changes for Alector
- The Consensus Analyst Price Target remained effectively unchanged, at $4.51.
- The Discount Rate for Alector remained effectively unchanged, at 6.92%.
- The Net Profit Margin for Alector remained effectively unchanged, at 18.39%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.